Free Newsletter
Pediatricians say kids should take statins
Good news for makers of cholesterol meds: The market has just expanded. For the first time, the American Academy of Pediatrics is recommending that kids as young as 8 years old be given cholesterol drugs in hopes of preventing future heart disease. The influential doctors' group also wants doctors to routinely test young children's cholesterol levels, which isn't commonly done now. That testing would identify kids in need of drug therapy.
The AAP says its advice is based on new evidence showing that greater heart-disease risks begin developing early in life. Previously, the group had advised consideration of the drugs if kids older than 10 had tried and failed to lose weight.
Four statins are FDA-approved for pediatric use (with some age and developmental caveats): Mevacor, or lovastatin; Zocor, or simvastatin; Pravachol, or pravastatin; and Lipitor, or atorvastatin. Of those, only Pfizer's Lipitor remains on patent. But doctors could of course choose other branded meds for kids off-label.
- read the APP's release
- see the story in the Washington Post
- check out the post at the New York Times' blog
Related Articles:
U.K. aims to put 1.5M on preventive statins
Study: Statins cut cancer by 25%
Study: Diabetics should take statins
Comments
I used to think the Pediatric societies were one of the few physician organizations not bought out by big pharma.
I guess I was wrong!
Yeah right - instead of educating kids toward healthier eating and getting exercise, just let them keep eating junk and playing video games, because now there's a DRUG to take the edge off the risks there -- Brilliant. Talk about perpetuating a downward spiral -- the suggestion of mitigating "health risk" in this fashion is ludicrous.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: